Figure 3

Progression free survival and overall survival. Kaplan–Meier curves including patient numbers at risk indicating PFS according to CTC status (A) and AR-V7 status (B) of patients undergoing ARTA treatment. (A, left panel) For the overall cohort, median PFS was 22 months (CI not estimable) and 8 months (CI 5.5–10.5) for CTC − patients and CTC + patients, respectively (p < 0.01). (A, right panel) Within the CTC + cohort, median PFS was 10 months (CI 8.9–11.1) and 6 months (CI 3.6–8.4) for AR-V7- patients and AR-V7 + patients, respectively, without statistical significance (p = 0.07). (B, left panel) For the overall cohort, median PFS was 16 months (CI 7.0–25.0) and 6 months (CI 3.6–8.4) for AR-V7- patients and AR-V7 + patients, respectively (p < 0.01). (B, right panel) Within the AR-V7- subgroup, median PFS was 22 months (CI not estimable) and 10 months (CI 8.9–11.1) for CTC − patients and CTC + patients, respectively (p = 0.03). Kaplan–Meier curves including patient numbers at risk indicating OS according to CTC status (C) and AR-V7 status (D) of patients undergoing ARTA treatment. (C, left panel) For the overall cohort, median OS was not reached for CTC − patients and 15 months (CI 8.7–21.3) for CTC + patients (p < 0.01). (C, right panel) Within the CTC + cohort, median OS was 27 months (CI 25.1–28.9) and 13 months (CI 9.2–16.8) for AR-V7- patients and AR-V7 + patients, respectively (p > 0.01), without statistical significance (p = 0.07). (D, left panel) For the overall cohort, median OS was 31 months (CI 25.2–36.8) and 13 months (CI 9.2–16.8) for AR-V7- patients and AR-V7 + patients, respectively (p < 0.01). (D, right panel) Within the AR-V7- subgroup, median OS was not reached and 27 months (CI 25.1–28.9) for CTC − patients and CTC + patients, respectively, (p = 0.02).